{"id":"W4413141479","doi":"10.1182/bloodadvances.2024015600","title":"Camidanlumab tesirine for relapsed or refractory classic Hodgkin lymphoma: a phase 2 study","year":2025,"lang":"en","type":"article","venue":"Blood Advances","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency; Spinal Cord Injury BC; Ottawa Hospital; University of Ottawa; Health Canada","funders":"Pharmacyclics; Genentech; Astellas Pharma; EUSA Pharma; Seagen; Regeneron Pharmaceuticals; Incyte; F. Hoffmann-La Roche; Kite Pharma; Gilead Sciences; Ipsen; BeiGene; Daiichi Sankyo Europe; University College London Hospitals NHS Foundation Trust; Sanofi; Swedish Orphan Biovitrum; Omeros Corporation; Spectrum Pharmaceuticals; Amgen; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Brentuximab vedotin; Internal medicine; Refractory (planetary science); Clinical endpoint; Adverse effect; Lymphoma; Surgery; Gastroenterology; Oncology; Clinical trial; Hodgkin lymphoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001191204,0.0005638411,0.0008813189,0.0001420725,0.0001640301,0.0005402237,0.0003204418,0.0004382699,0.001920169],"category_scores_gemma":[0.0004315095,0.0002246724,0.0006584153,0.0001500428,0.0003104456,0.0003823169,0.0001840639,0.001046603,0.0004035065],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00042225,"about_ca_system_score_gemma":0.0006256817,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004001622,"about_ca_topic_score_gemma":0.001262307,"domain_scores_codex":[0.9998153,0.000086929,0.00001207984,0.00002928156,0.00002633281,0.00003011423],"domain_scores_gemma":[0.9997616,0.000044789,0.00004976525,0.00002378762,0.0000238269,0.0000961067],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4831046,0.06952909,0.03896044,0.002423925,0.004873886,0.0009748484,0.0004934989,0.002406189,0.1103433,0.0003782455,0.007355584,0.2791563],"study_design_scores_gemma":[0.4812073,0.4409235,0.05678412,0.00009723396,0.001714973,0.001199879,0.0001170385,0.002232028,0.008147876,0.0001844318,0.007344534,0.00004719173],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9948938,0.002622131,0.0002746819,0.0001251681,0.00003387778,0.0008179196,0.000414523,0.00003987208,0.0007779645],"genre_scores_gemma":[0.9942592,0.001544533,0.0008404251,0.000441931,0.00007349211,0.0006437495,0.001096275,0.00001186744,0.001088592],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001920169,"threshold_uncertainty_score":0.006423593,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02168455737675362,"score_gpt":0.352881388360296,"score_spread":0.3311968309835424,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}